

Pertuzumab Biosimilar, Endotoxin 0.05 EU/mg

Catalog No.: YR0042

Basic Information

Molecular Weight

150 kDa

Endotoxin

<0.05EU/mg (<0.00005EU/μg)
Determined by LAL gel clotting assay

Sterility

0.2 μm filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Pertuzumab, a humanized monoclonal antibody, inhibits HER dimerization and is used for the treatment of HER2-positive metastatic breast cancer, in combination with trastuzumab and docetaxel. By binding to HER2, Pertuzumab inhibits the dimerization of HER2 with other HER receptors, resulting in slowed tumor growth.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Pertuzumab

Isotype

Human IgG1 kappa

Immunogen

Human ErbB-2 / Her2

Recommended Isotype Control(s)

In Vivo Grade Recombinant Human IgG1 Kappa Isotype Control Antibody

Recommended Dilution Buffer

1×PBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility

Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)